Investor Presentation

AI summary - Q1FY27 revenue grew 25% YoY to ₹1300 Cr; EBITDA up 37% YoY to ₹209 Cr; PAT rose 41% YoY to ₹106 Cr - Specialty Chemicals revenue up 11% YoY; EBITDA margin 26% supported by Fine Chemicals and CDMO growth - Nutrition segment revenue increased 36% YoY with 15% EBITDA margin; strong volume and pricing gains - Chemical Intermediates revenue rose 38% YoY; EBITDA margin expanded to 11% on pricing and cost control - New Multi-Purpose Plant commissioning on track by end CY26; strong CDMO pipeline with 25+ confirmed molecules - Electronics/semiconductor segment gaining traction with dedicated R&D lab and clean room planned - FY27 growth expected from Specialty Chemicals, Nutrition, and Acetyls recovery; sequential revenue and EBITDA improvement anticipated - Operations target ₹100 Cr lean savings in FY27; multiple safety awards and ESG recognitions received - Completed Remidex Pharma integration; evaluating new growth opportunities in Electronics, Cosmetics, Nutrition